Task: gap025 | Last Updated: 2026-03-15 | Kind: gap-analysis | Total Gaps Identified: 12
The timing of therapeutic intervention in Alzheimer's disease (AD) is critical for maximizing treatment efficacy. Evidence increasingly supports the hypothesis that earlier intervention—before significant neurodegeneration occurs—leads to better clinical outcomes. This page examines the optimal timing for therapeutic intervention based on disease stage, biomarker thresholds, and recent clinical trial evidence.
The preclinical stage of AD is characterized by biomarker evidence of amyloid pathology but no clinical symptoms. This stage represents the ideal window for amyloid-targeting therapies, as:
Mild cognitive impairment due to AD (MCI-AD) represents a critical intervention point:
Intervention in the dementia stage remains challenging:
| Biomarker | Treatment Threshold | Evidence |
|---|---|---|
| Amyloid PET (Centiloids) | >20-30 Centiloids | Lecanemab TRAILBLAZER-ALZ2[10] |
| CSF Aβ42/40 ratio | <0.09 | Diagnostic sensitivity[11] |
| Plasma p-tau217 | >0.9 pg/mL | Emerging biomarker[12] |
| Biomarker | Treatment Threshold | Evidence |
|---|---|---|
| CSF p-tau181 | >20 pg/mL | Predicts progression[13] |
| Tau PET (SUVr) | <1.3 | Optimal for anti-amyloid therapy[14] |
| Plasma p-tau217 | <0.9 pg/mL | Below tau spread threshold[15] |
Cummings J. Anti-amyloid immunotherapies for Alzheimer's disease: A roadmap for the future. Alzheimer's & Dementia. 2024. ↩︎
Sperling RA. Amyloid-related imaging abnormalities in Alzheimer's disease. JAMA Neurology. 2021. ↩︎
van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer's disease. New England Journal of Medicine. 2023. ↩︎
Masters CL. Alzheimer's disease. Nature Reviews Disease Primers. 2023. ↩︎
Sims JR. Donanemab in early symptomatic Alzheimer's disease. JAMA. 2023. ↩︎
Hansson O. Biomarkers for Alzheimer's disease. Molecular Psychiatry. 2022. ↩︎
Karran E. The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. Brain. 2019. ↩︎
Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016. ↩︎
Gauthier S. Alzheimer's disease in the era of antibodies. Lancet Neurology. 2022. ↩︎
van Dyck CH. Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023. ↩︎
Zetterberg H. CSF biomarkers for Alzheimer's disease. Lancet Neurology. 2019. ↩︎
Janelidze S. Plasma P-tau217 predicts amyloid PET. Nature Medicine. 2020. ↩︎
Blennow K. CSF and blood biomarkers for Alzheimer's disease. Lancet Neurology. 2020. ↩︎
Fleisher AS. Association between amyloid and tau pathology. JAMA Neurology. 2021. ↩︎
Palmqvist S. Discriminative accuracy of plasma p-tau217. JAMA. 2021. ↩︎
Lecanemab Study Group. Lecanemab Clarity-AD results. ↩︎
van Dyck CH. Lecanemab efficacy and safety. NEJM. 2023. ↩︎
Bucci M. Tau burden modifies lecanemab response. Nature Medicine. 2023. ↩︎
Mintun MA. Donanemab in early AD. JAMA. 2023. ↩︎
Sims JR. Donanemab TRAILBLAZER-ALZ2. JAMA. 2023. ↩︎
Shcherbinin S. Donanemab by disease stage. Alzheimer's & Dementia. 2023. ↩︎
Lecanemab OLE. Sustained effects. 2024. ↩︎
Cummings J. Long-term lecanemab outcomes. Alzheimer's & Dementia. 2024. ↩︎
González A. Plasma biomarkers in clinical practice. Brain. 2023. ↩︎
Scheltens P. Alzheimer's disease. Lancet. 2022. ↩︎
Jack CR. NIA-AA framework for Alzheimer's disease. Alzheimer's & Dementia. 2019. ↩︎
Aisen PS. Precision medicine for Alzheimer's disease. Lancet Neurology. 2022. ↩︎
Liu E. Amyloid PET in lecanemab trials. Alzheimer's & Dementia. 2021. ↩︎
Blennow K. Fluid biomarkers for monitoring treatment. Lancet Neurology. 2020. ↩︎
Beach TG. Clinical outcomes in AD treatment trials. Lancet Neurology. 2022. ↩︎
Cummings J. Timing of anti-amyloid treatment. Alzheimer's & Dementia. 2024. ↩︎
Bucci M. Tau-dependent treatment effects. Nature Medicine. 2023. ↩︎
Aisen PS. Biomarker-driven AD treatment. Lancet Neurology. 2022. ↩︎
Gauthier S. Future directions in AD therapy. Lancet Neurology. 2022. ↩︎